Show simple item record

dc.contributor.authorMorris, G
dc.contributor.authorBortolasci, CC
dc.contributor.authorPuri, BK
dc.contributor.authorOlive, L
dc.contributor.authorMarx, W
dc.contributor.authorO'Neil, A
dc.contributor.authorAthan, E
dc.contributor.authorCarvalho, A
dc.contributor.authorMaes, M
dc.contributor.authorWalder, K
dc.contributor.authorBerk, M
dc.date.accessioned2020-12-16T23:41:16Z
dc.date.available2020-12-16T23:41:16Z
dc.date.issued2021-01-01
dc.identifierpii: S0024-3205(20)31370-9
dc.identifier.citationMorris, G., Bortolasci, C. C., Puri, B. K., Olive, L., Marx, W., O'Neil, A., Athan, E., Carvalho, A., Maes, M., Walder, K. & Berk, M. (2021). Preventing the development of severe COVID-19 by modifying immunothrombosis. LIFE SCIENCES, 264, https://doi.org/10.1016/j.lfs.2020.118617.
dc.identifier.issn0024-3205
dc.identifier.urihttp://hdl.handle.net/11343/254468
dc.description.abstractBACKGROUND: COVID-19-associated acute respiratory distress syndrome (ARDS) is associated with significant morbidity and high levels of mortality. This paper describes the processes involved in the pathophysiology of COVID-19 from the initial infection and subsequent destruction of type II alveolar epithelial cells by SARS-CoV-2 and culminating in the development of ARDS. MAIN BODY: The activation of alveolar cells and alveolar macrophages leads to the release of large quantities of proinflammatory cytokines and chemokines and their translocation into the pulmonary vasculature. The presence of these inflammatory mediators in the vascular compartment leads to the activation of vascular endothelial cells platelets and neutrophils and the subsequent formation of platelet neutrophil complexes. These complexes in concert with activated endothelial cells interact to create a state of immunothrombosis. The consequence of immunothrombosis include hypercoagulation, accelerating inflammation, fibrin deposition, migration of neutrophil extracellular traps (NETs) producing neutrophils into the alveolar apace, activation of the NLRP3 inflammazome, increased alveolar macrophage destruction and massive tissue damage by pyroptosis and necroptosis Therapeutic combinations aimed at ameliorating immunothrombosis and preventing the development of severe COVID-19 are discussed in detail.
dc.languageEnglish
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD
dc.titlePreventing the development of severe COVID-19 by modifying immunothrombosis
dc.typeJournal Article
dc.identifier.doi10.1016/j.lfs.2020.118617
melbourne.affiliation.departmentPsychiatry
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.departmentAcademic Services and Registrar
melbourne.source.titleLife Sciences
melbourne.source.volume264
melbourne.source.pages118617-
melbourne.elementsid1469142
melbourne.openaccess.urlhttps://europepmc.org/articles/PMC7574725?pdf=render
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574725
melbourne.openaccess.statusPublished version
melbourne.contributor.authorBerk, Michael
melbourne.contributor.authorO'Neil, Adrienne
melbourne.contributor.authorWALDER, KENNETH
dc.identifier.eissn1879-0631
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record